$201 Million is the total value of DAFNA Capital Management LLC's 83 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STXS | STEREOTAXIS INC | $14,789,000 | -10.7% | 13,680,554 | 0.0% | 7.35% | +8.2% | |
| BPMC | BLUEPRINT MEDICINES CORP | $4,997,000 | -30.9% | 92,691 | 0.0% | 2.48% | -16.4% | |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $4,839,000 | -11.6% | 77,242 | 0.0% | 2.41% | +7.1% | |
| ALDR | ALDER BIOPHARMACEUTICALS INC | $4,059,000 | -38.4% | 396,013 | 0.0% | 2.02% | -25.5% | |
| LMNX | LUMINEX CORP | $3,198,000 | -23.8% | 138,391 | 0.0% | 1.59% | -7.7% | |
| RADIUS HEALTH INCnote 3.000% 9/0 | $3,064,000 | -0.5% | 4,000,000 | 0.0% | 1.52% | +20.5% | ||
| FOMX | FOAMIX PHARMACEUTICALS LTD | $2,901,000 | -37.3% | 808,000 | 0.0% | 1.44% | -24.1% | |
| WVE | WAVE LIFE SCIENCES LTD | $2,014,000 | -15.9% | 47,900 | 0.0% | 1.00% | +1.9% | |
| INSULET CORPnote 1.375% | $1,590,000 | -16.7% | 1,500,000 | 0.0% | 0.79% | +0.9% | ||
| XENE | XENON PHARMACEUTICALS INC | $1,500,000 | -52.2% | 237,683 | 0.0% | 0.75% | -42.1% | |
| INCY | INCYTE CORP | $1,367,000 | -7.9% | 21,500 | 0.0% | 0.68% | +11.5% | |
| NTUS | NATUS MEDICAL INC | $1,290,000 | -4.5% | 37,900 | 0.0% | 0.64% | +15.5% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $1,267,000 | -29.9% | 118,500 | 0.0% | 0.63% | -15.1% | |
| JNJ | JOHNSON AND JOHNSON | $1,213,000 | -6.6% | 9,400 | 0.0% | 0.60% | +13.1% | |
| MGNX | MACROGENICS INC | $994,000 | -40.8% | 78,305 | 0.0% | 0.49% | -28.3% | |
| ARDX | ARDELYX INC | $846,000 | -58.9% | 472,859 | 0.0% | 0.42% | -50.2% | |
| URGN | UROGEN PHARMA LTD | $646,000 | -8.8% | 15,000 | 0.0% | 0.32% | +10.3% | |
| SCYX | SCYNEXIS INC | $613,000 | -59.9% | 1,272,927 | 0.0% | 0.30% | -51.4% | |
| CDTX | CIDARA THERAPEUTICS INC | $500,000 | -46.6% | 212,766 | 0.0% | 0.25% | -35.2% | |
| SPRO | SPERO THERAPEUTICS INC | $431,000 | -41.4% | 70,000 | 0.0% | 0.21% | -29.1% | |
| RDUS | RADIUS HEALTH INC | $338,000 | -7.4% | 20,500 | 0.0% | 0.17% | +12.0% | |
| DEXCOM INCnote 0.750% 5/1 | $336,000 | -12.3% | 250,000 | 0.0% | 0.17% | +6.4% | ||
| MASI | MASIMO CORPORATION | $322,000 | -13.9% | 3,000 | 0.0% | 0.16% | +3.9% | |
| ADXS | ADVAXIS INC | $317,000 | -79.8% | 1,666,666 | 0.0% | 0.16% | -75.4% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $316,000 | -28.5% | 137,600 | 0.0% | 0.16% | -13.7% | |
| APTX | APTINYX INC | $240,000 | -42.9% | 14,500 | 0.0% | 0.12% | -30.8% | |
| SLGL | SOL GEL TECHNOLOGIES LTD | $211,000 | -19.8% | 35,000 | 0.0% | 0.10% | -2.8% | |
| ALDER BIOPHARMACEUTICALS INCnote 2.500% 2/0 | $201,000 | -25.3% | 250,000 | 0.0% | 0.10% | -9.1% | ||
| BTX | BIOTIME INC | $91,000 | -61.3% | 100,000 | 0.0% | 0.04% | -53.6% | |
| BLCM | BELLICUM PHARMACEUTICALS INC | $88,000 | -52.4% | 30,000 | 0.0% | 0.04% | -42.1% | |
| NEOS | NEOS THERAPEUTICS INC | $45,000 | -66.2% | 27,500 | 0.0% | 0.02% | -60.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.